New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
06:11 EDTIMUCImmunoCellular anticipates strategies and milestones for ICT-107
ImmunoCellular Therapeutics provided an update on the Company's anticipated 2014 corporate strategies and milestones. Company said "As we enter 2014, we are focused on advancing our pipeline of cancer vaccines, and on creating and delivering value to all our stakeholders. We are committed to making the best data-driven decisions we can about how we move forward and invest our resources. We are confident that our clinical programs have meaningful therapeutic and commercial potential, and intend to ensure that our strategies are driven by appropriate medical and scientific rationales. We are also confident that we have more than enough resources to achieve our near-term goals and that we will continue our progress in building a leading cancer immunotherapy company and transforming the treatment of cancer." The next steps for ICT-107 include: continue to monitor overall survival for patients in the phase II trial; analyze immunological data relating to the patients and the vaccine, to inform the phase III design and potential patient selection; antigen expression in patient tumor samples, to determine if there is a correlation between the expression of certain antigens in patients' tumors and OS and PFS; dendritic cell characterization data, focusing on two indicators of dendritic cell activation that are statistically predictive of OS in the treated patients; analysis of patient samples for vaccine-induced T-cell activation, to enable determination of a potential relationship between vaccine responders and OS.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
09:15 EDTIMUCImmunoCellular to host conference call
President & CEO Gengos discusses the ICT-107 updated data presented at the recently-held Society for Neuro-Oncology's 19th Annual Scientific Meeting on a conference call to be held on November 18 at 5 pm. Webcast Link
November 14, 2014
06:10 EDTIMUCImmunoCellular jpresents positive Phase II data for ICT-107
ImmunoCellular announces the presentation of updated efficacy data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107. Consistent with prior data presentations in December 2013 and June 2014, the results demonstrate a statistically significant progression-free survival benefit, and a numeric overall survival benefit in ICT-107 treated patients compared to the control group. The ICT-107 treatment effect continues to be strongest in the pre-defined HLA-A2 subgroup of patients in which the MGMT methylated patients showed the largest treatment effect, with a significant PFS advantage over the control group, and continued potential for the OS advantage to move toward significance as more events occur. There were no differences in adverse events between the ICT-107 treated group and the control group. The company is utilizing all available information from the controlled phase II trial to design phase III testing in order to increase its probability of success, including the timing of randomization within the standard-of-care treatment these patients receive, in an attempt to limit the number of patients who are "early progressors" and unlikely to respond to therapy.
November 10, 2014
06:03 EDTIMUCImmunoCellular reports Q3 EPS (3c), consensus (6c)

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use